2012
Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients
Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M. Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients. HIV Medicine 2012, 13: 345-351. PMID: 22276745, DOI: 10.1111/j.1468-1293.2011.00981.x.Peer-Reviewed Original ResearchConceptsCD4 cell countViral load changesWeek 12Replication capacityPredictive valueCell countCD4 cell count responseHIV-1 replication capacityAntiretroviral treatment responseHIV replication capacityImmediate salvage therapyPhenotypic susceptibility scoresDrug-free periodPhenotypic resistance testingCell count responseAdditional predictive valueMultivariate regression analysisTreatment reinitiationSalvage therapyWeek 24ARV therapyViral loadPrognostic valueARV treatmentAntiretroviral trials
2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial
Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, Holodniy M, Brown ST, Youle M, Gazzard B, Team O. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Contemporary Clinical Trials 2003, 24: 481-500. PMID: 12865041, DOI: 10.1016/s0197-2456(03)00029-1.Peer-Reviewed Original ResearchConceptsOPTIMA trialClinical trialsTherapeutic strategiesHuman immunodeficiency virus-infected individualsVirus-infected individualsDrug-free periodVeterans Affairs hospitalDifferent therapeutic strategiesYears of intakeNovel therapeutic strategiesAnti-HIV drugsAntiretroviral therapyStrategy armART drugsTrial designHIV drugsStudy durationHospitalTrialsRelative efficacyDrugsTherapyOptimum trial designYearsMulticenter